Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

NCT03396445

Conditions
Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +15 more
Locations
  • University of South Alabama, Mitchell Cancer Institute ( Site 0020) Mobile, Alabama, United States
  • Florida Cancer Specialists ( Site 0002) Sarasota, Florida, United States
  • The West Clinic, P.C. ( Site 0021) Germantown, Tennessee, United States
  • FALP-UIDO ( Site 0502) Santiago, Region M. de Santiago, Chile
View all 18 locations
View Trial Details
Completed

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

NCT03010176

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Alabama ( Site 0009) Birmingham, Alabama, United States
  • University of California San Francisco ( Site 0007) San Francisco, California, United States
  • UCSF ( Site 0015) San Francisco, California, United States
  • UCLA Medical Center ( Site 0005) Santa Monica, California, United States
View all 19 locations
View Trial Details
Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

NCT04220866

Conditions
Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +13 more
Locations
  • UCLA Hematology & Oncology ( Site 0005) Los Angeles, California, United States
  • University of California at San Francisco ( Site 0006) San Francisco, California, United States
  • Henry Ford Hospital ( Site 0012) Detroit, Michigan, United States
  • Washington University ( Site 0021) St Louis, Missouri, United States
View all 34 locations
View Trial Details
Completed

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

NCT04700072

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • The Angeles Clinic and Research Institute ( Site 4009) Los Angeles, California, United States
  • UCLA Hematology & Oncology ( Site 4004) Los Angeles, California, United States
  • Providence Saint John's Health Center ( Site 4010) Santa Monica, California, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 4012) Aurora, Colorado, United States
View all 36 locations
View Trial Details
Completed

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

NCT04303169

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • The Angeles Clinic and Research Institute ( Site 3009) Los Angeles, California, United States
  • Providence Saint John's Health Center ( Site 3010) Santa Monica, California, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 3012) Aurora, Colorado, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 3022) Baltimore, Maryland, United States
View all 29 locations
View Trial Details
Completed

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • Moores Cancer Center ( Site 0116) La Jolla, California, United States
  • The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131) Los Angeles, California, United States
  • California Pacific Medical Center - Pacific Campus ( Site 0111) San Francisco, California, United States
View all 205 locations
View Trial Details
Completed

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

NCT04934722

Conditions
Metastatic Hormone-sensitive Prostate Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Peking University First Hospital ( Site 0800) Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital ( Site 0802) Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital ( Site 0815) Chongqing, Chongqing Municipality, China
  • The First Affiliated Hospital of Xiamen University (Site 0816) Xiamen, Fujian, China
View all 24 locations
View Trial Details
Completed

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

NCT03062358

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Anhui Provincial Hospital ( Site 0032) Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University ( Site 0005) Hefei, Anhui, China
  • Fuzhou General Hospital of Nanjing Military Command ( Site 0019) Fuzhou, Fujian, China
  • The First People s Hospital of Foshan ( Site 0033) Foshan, Guangdong, China
View all 41 locations
View Trial Details
Completed

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

NCT04716933

Conditions
Nonsquamous Non-small Cell Lung Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Peking Union Medical College Hospital ( Site 0108) Beijing, Beijing Municipality, China
  • Cancer Hospital Chinese Academy of Medical Science ( Site 0117) Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital ( Site 0120) Beijing, Beijing Municipality, China
  • The Second Hospital Affiliated to AMU ( Site 0119) Chongqing, Chongqing Municipality, China
View all 19 locations
View Trial Details

Related conditions